Project Grant R01AI187458
Award Date
7/14/25
Completion Date
6/30/29
Dollars Obligated
$2.8M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,194,992 to the University of California, San Diego (UC San Diego) to conduct research on the roles and regulation of tissue-resident CD8 T cells during a persistent viral infection. The key objectives are to: (1) evaluate the role of tissue-resident CD8 T cells in intestinal hyper-permeability and colitis during a sustained viral...
The federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $972,151 to The Regents of the University of California, San Francisco (UCSF) to conduct systematic genetic investigations of the mechanisms governing immunogenic cell death (ICD). The project aims to enhance understanding of the molecular signals and cellular processes that determine whether phagocytes...
The federal Project Grant award R21AI185033 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of the APOBEC3B enzyme in the innate immune response against RNA viruses such as SARS-CoV-2, HIV-1, and Hepatitis B. The $228,435 award, effective January 2, 2025 through December 31, 2026, will fund research at the University of California, Irvine to identify novel...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $189,713 to Northwestern University to conduct research on the role of the PIM1 kinase in regulating the metabolic adaptation of CD8 effector T cells during chronic viral infections. The research aims to elucidate the IL-21-PIM1 signaling axis and its impact on the differentiation and function of late-stage...
This federal Project Grant award of $658,657, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at the University of Virginia on the biophysical and functional coupling of protein condensates to ordered lipid domains in T-cells. The research aims to reveal the mechanisms by which protein condensates and membrane domains cooperatively regulate T-cell signal transduction and...
This federal Project Grant award of $643,718 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how interferon-regulatory factors (IRFs) and STAT transcription factors remodel the epigenome and chromosome organization of macrophages to reprogram their immune responses. The research aims to: 1) dissect the roles of innate immune IRFs in de novo enhancer formation, 2)...
This federal Project Grant award of $705,557 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to better understand the coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearance. The primary objectives are to determine the contribution of monocytes in promoting T cell responses and viral control within the respiratory tract, and to define the effector mechanisms of...
This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...